HTG Molecular Diagnostics Priced, Nasdaq: HTGM

Markets a diagnostic platform for complex molecular profiling.

Industry: Health Care

Latest Trade: $2.69 0.00 (0.0%)

First Day Return: -1.6%

Return from IPO: -80.8%

Industry: Health Care

We are a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. Our HTG Edge automated platform can quickly, robustly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies. Our objective is to establish the HTG Edge platform as a standard in molecular profiling and make this capability accessible to all molecular labs from research to the clinic. We believe that our target customers desire high quality molecular profiling information in a multiplexed panel format from increasingly smaller samples, with the ability to do this locally to minimize turnaround time and cost. The HTG Edge platform was designed to meet these needs and is empowering pathologists, clinicians and molecular labs to directly control the molecular profiling of patient samples.
more less
IPO News for HTG Molecular Diagnostics
more
IPO Data
IPO File Date 12/30/2014
Offer Price $14.00
Price Range $13.00 - $15.00
Offer Shares (mm) 3.6
Deal Size ($mm) $50
IPO Data
IPO Date 05/06/2015
Offer Price $14.00
Price Range $13.00 - $15.00
Offer Shares (mm) 3.6
Deal Size ($mm) $50
Underwriters
more
Company Data
Headquarters Tucson, AZ
Founded 1997
Employees 77
Website www.htgmolecular.com